Soligenix (SNGX) to Release Quarterly Earnings on Friday

Soligenix (NASDAQ:SNGX) will likely be announcing its Q1 2026 results before the market opens on Friday, May 8th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Soligenix Stock Down 7.8%

SNGX opened at $0.32 on Wednesday. The firm has a 50-day simple moving average of $1.13 and a two-hundred day simple moving average of $1.30. Soligenix has a 52 week low of $0.31 and a 52 week high of $6.23. The company has a market capitalization of $3.28 million, a PE ratio of -0.09 and a beta of 1.31.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Soligenix in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Soligenix currently has an average rating of “Hold” and an average target price of $6.00.

Institutional Trading of Soligenix

Hedge funds have recently made changes to their positions in the business. Armistice Capital LLC purchased a new stake in shares of Soligenix during the 3rd quarter valued at about $821,000. Geode Capital Management LLC raised its position in shares of Soligenix by 88.8% during the 4th quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 37,811 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Soligenix during the 3rd quarter valued at about $102,000. Virtu Financial LLC purchased a new stake in shares of Soligenix during the 3rd quarter valued at about $59,000. Finally, Banco BTG Pactual S.A. purchased a new stake in shares of Soligenix during the 3rd quarter valued at about $54,000. 3.60% of the stock is currently owned by hedge funds and other institutional investors.

Soligenix Company Profile

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.